NAYA NAYA Biosciences Inc: Rentabilitas dodolan miturut bathi resik

Logo grafis NAYA Biosciences (NAYA)

NAYA Biosciences (NAYA) prospects in gene modification and reproductive medicine are driving the current trend, while the company's sales margins demonstrate a new parameter -122.80. Growth is based on the closed patents of the FLEX-NK platform, although the market currently prices in the assets speculatively, awaiting management's success. Profitability analysis helps avoid overpaying for the stock during periods of hype.

NAYA Biosciences Corp (NAYA) - Margin resik saka 04.07.2022 nganti 28.04.2025

Rincian analitis perusahaan NAYA Biosciences

- rega saham lan prakiraan rega para ahli:
Analisis kabeh metrik perusahaan:NAYA Biosciences Inc - NAYA
Produk asil prodhuksi NAYA Bio

Analyzing the efficiency of converting revenue into profit is critical for selecting the fundamental leaders of the sector. This metric measures the share of net income after deducting all operating expenses relative to total sales volume. For NAYA Biosciences (NAYA), which relies on external investments for antibody development, this calculation reveals the extent of its dependence on capital injections. By analyzing the history of net profit margins, an investor can uncover hidden business degradation in the absence of stable commercial products.

Pesaing utama

ONC: Margin dodolan resik|Margin resik Halozyme Inc. (HALO)|Margin resik RevMed|Rentabilitas dodolan resik AAPG (Ascentage Pharma Group)|Margin dodolan resik CGON|UroGen Pharma - Rentabilitas dodolan resik|Bicara Therapeutics - Rentabilitas dodolan miturut bathi resik|Margin dodolan resik Personalis Inc PSNL|Erasca Oncology - Margin dodolan resik|Tingkat bathi resik DCTH (Delcath Corp)|YMAB: Margin dodolan resik|AURA - Margin dodolan perusahaan|CADL (Candel Therapeutics Inc.) - Margin dodolan resik|Rentabilitas dodolan resik ARAY (Accuray)|Rentabilitas dodolan miturut bathi resik SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Margin resik|Margin resik Citius Oncology, Inc. CTOR|HURA - Rentabilitas dodolan miturut bathi resik|protaratx.com - Margin dodolan resik|FATE - Margin dodolan resik|WHWK: Margin dodolan resik|TScan Therapeutics (TCRX) - Margin dodolan resik|Margin resik Champions Oncology|Margin resik XBIT|Margin dodolan resik CVM|Rentabilitas dodolan miturut bathi resik OS Therapies Inc. OSTX|Margin resik Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Margin resik|ANL - Margin resik|Margin resik verupharma.com|TPST: Margin dodolan resik|XLO - Margin dodolan perusahaan|Margin resik Renovaro|Margin dodolan resik muraloncology.com|Margin dodolan resik KAPA|Margin dodolan perusahaan OnKure Therapeutics, Inc.|Margin dodolan resik GDTC (w2.cytomed.sg)|CRIS - Rentabilitas dodolan miturut bathi resik|Apollomics - Margin dodolan resik|Tharimmune Corp (THAR) - Rentabilitas dodolan miturut bathi resik|ADVB: Margin dodolan resik|Rentabilitas dodolan miturut bathi resik Genprex|CLDI (Calidi Biotherapeutics, Inc.) - Margin dodolan resik|Rentabilitas dodolan resik SBFM (Sunshine Biopharma)|Margin resik Xenetic Bio (XBIO)|Margin resik SLRX (Salarius Pharma)|Kitov Pharma - Rentabilitas dodolan miturut bathi resik|American Oncology Network (AONC) - Margin resik|BeiGene - Margin dodolan resik|Checkpoint Therapeutics, Inc. (CKPT) - Rentabilitas dodolan miturut bathi resik|ELEV (Elevation Oncology, Inc.) - Rentabilitas dodolan miturut bathi resik|iCAD Inc. - Tingkat bathi resik|Rentabilitas dodolan miturut bathi resik IKNA|Margin dodolan resik notablelabs.com|Rentabilitas dodolan miturut bathi resik VIRX (Viracta Therapeutics Inc.)|MOR - Margin resik|Margin dodolan resik AAPGV (Ascentage)